CAS NO: | 57420-46-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Barlerin (8-O-Acetyl shanzhiside methyl ester) is an iridoid glucoside isolated from the leaves ofLamiophlomis rotataKudo, a Chinese folk medicinal plant in Xi-zang. Barlerin (8-O-Acetyl shanzhiside methyl ester) could inhibtNF-κB. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Treatment of SH-SY5Y cells with Barlerin (8-O-Acetyl shanzhiside methyl ester) blocks TNF-α-induced nuclear transcription factor κB (NF-κB) activation and decreases high-mobility group box-1 (HMGB-1) expression.[1]. Treatment of H9c2 cells with Barlerin (8-O-Acetyl shanzhiside methyl ester) 9 μM blocks TNF-α-induced NF-κB phosphorylation by blocking High-mobility group box1 (HMGB1) expression[2]. | ||||||||||||||||
体内研究 (In Vivo) | Barlerin (8-O-Acetyl shanzhiside methyl ester) 40 mg/kg demonstrates significant neuroprotective effect even after delayed administration at 4 hr after I/R. Barlerin 40 mg/kg attenuates the histopathological damage, decreases brain swelling, inhibits NF-κB activation and reduces HMGB-1 expression in ischaemic brain tissue[1]. Barlerin (8-O-Acetyl shanzhiside methyl ester) significantly promotes angiogenesis in the ischaemic brain and improves functional outcome after stroke. Barlerin also significantly increases vascularization compared with vehicle treatment. It increases the expression of VEGF, Ang1, phosphorylation of Tie2 and Akt VEGF[3]. Barlerin (8-O-Acetyl shanzhiside methyl ester) significantly shortens capillary blood clotting time and reduces blood loss volume, but does not influence mice activated partial thromboplastin time, prothrombin time or thrombin time. It significantly prolongs euglobulin clot lysis time in hyperfibrinolysis mice[4]. | ||||||||||||||||
分子量 | 448.42 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C19H28O12 | ||||||||||||||||
CAS 号 | 57420-46-9 | ||||||||||||||||
中文名称 | 8-O-乙酰山栀苷甲酯 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(223.01 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|